Article
Design, synthesis, and biological evaluation of novel probe-quality EGFR degraders targeting wild-type and Del19 mutation.
Bioorganic & medicinal chemistry letters - 1 Sept 2026
Gong Xiaomeng, Zhang Mingyue, Min Jingli, Jiang Lili, Liu Pei, Pan Youlu, Chen Yinqiao, Huang Wenhai
Abstract excerpt
Epidermal growth factor receptor (EGFR) serves as a key therapeutic target for solid tumors such as non-small cell lung cancer (NSCLC), where its mutations and overexpression often lead to sustained activation of oncogenic signaling pathways. This study represents a comparative analysis of multiple targeted chimeric degradation technologies targeting EGFR allosteric sites, aiming to provide clearer guidance for...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.